Company intelligence / Profile preview

Beijing Kaiyingeling Biotechnology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Kawin Geling Biotechnology is a Chinese biopharmaceutical company and a subsidiary of Beijing Kawin Technology, focused on the development of antiviral therapies. The company is best known for its work in the hepatitis C (HCV) space, where it has successfully developed and commercialized direct-acting antivirals (DAAs). Its key products include kobitolvir (an NS5A inhibitor) and simeprevir (an NS3/4A protease inhibitor), which are used in combination to provide effective treatment for chronic HCV. Based in Beijing, the company leverages its R&D capabilities to address significant unmet needs in infectious diseases within the Chinese healthcare market.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Kaiyingeling Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kaiyingeling Biotechnology.

Explore the full profile